VAXART INC. - COMMON STOCK

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

13 Jun 2024 16:15:11 By Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 May 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

13 May 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

07 May 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

30 Apr 2024 08:00:39 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

27 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

20 Mar 2024 08:00:13 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Full Year 2023 Financial Results

14 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Vaxart to Host Full Year 2023 Business Update and Financial Results Conference Call on March 14

07 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart, Inc. Appoints Steven Lo as President, Chief Executive Officer, and Director

06 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating Its Next-Generation Vaccine Candidates Elicit Mucosal and Systemic Immunogenicity and Reduce Viral Shedding after SARS-CoV-2 Challenge

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

19 Jan 2024 08:30:00 By Nasdaq GlobeNewswire

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

16 Jan 2024 09:25:20 By Nasdaq GlobeNewswire

Vaxart, Inc. Announces Management Change

16 Jan 2024 09:22:58 By Nasdaq GlobeNewswire

Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

21 Dec 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart Provides Business Update and Reports Third Quarter 2023 Financial Results

02 Nov 2023 16:01:22 By Nasdaq GlobeNewswire

Vaxart Doses First Subject in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Host Third Quarter 2023 Business Update and Financial Results Conference Call on November 2

26 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Present at World Vaccine Congress Europe 2023 on October 18-19

11 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Vaxart to Participate in Fireside Chat at 2023 Cantor Global Healthcare Conference

21 Sep 2023 08:00:00 By Nasdaq GlobeNewswire